anavar only cycle

From the blood and lymphatic system: very rarely – neutropenia, thrombocytopenia, agranulocytosis, lymphopenia, isolated cases of pancytopenia.

For the skin: very rarely – psoriasis-like rash, exacerbation of psoriasis, acute generalized pustular rash.

Allergic reactions: very often – rash, hives; very rarely – angioneurotic edema, malignant epidermal erythema (Stevens-Johnson syndrome), anaphylactoid reactions, toxic epidermal necrolysis (Lyell’s syndrome).

From the musculoskeletal system: very often anavar only cycle – arthralgia, myalgia.

On the part of the central and peripheral nervous system: often – headache; rarely – paresthesia, gipostezii, dizziness; rarely -depressiya, anxiety.

On the part of the organ of hearing and labyrinth disorders: very rare – vertigo.

Other: rarely – malaise, weakness; very rare – systemic lupus erythematosus, including cutaneous form.

Overdosing Symptoms: nausea, vomiting, headache, dizziness, gastralgia, frequent urination, rash. Treatment: gastric lavage followed by activated carbon. If necessary spend symptomatic therapy.

Interaction with other drugs
is required terbinafine dose adjustment while the use of inhibitors and inducers of cytochrome anavar only cycle isoenzymes, which can slow down and speed up the excretion of terbinafine from the body. Cimetidine reduces terbinafine clearance rate of 30% and increases the rate of excretion of rifampicin 100% terbinafine. Studies in vitro and in vivo showed that terbinafine inhibits isozyme , gives metabolism tricyclic antidepressants, selective serotonin reuptake inhibitors (desipramine, fluvoxamine), beta-blockers (metoprolol, propranolol), antiarrhythmics (flecainide, propafenone), monoamine oxidase inhibitors B (selegiline) and antipsychotic agents (chlorpromazine, haloperidol).

Terbinafine does not influence the rate of excretion tolbutamina, terfinadina, triazolam, oral contraceptives, which are metabolised via other cytochrome.

Terbinafine does not influence the rate of excretion of antipyrine and digoxin. At the same time taking terbinafine and oral contraceptives may develop irregular menstruation. Terbinafine may enhance the effectiveness of caffeine, due to the increase of its concentration in plasma and reduce the clearance rate from the body by 21%.

Terbinafine may decrease the rate of excretion of desipramine by 82%.

Terbinafine may reduce the effectiveness of cyclosporine, by reducing plasma concentration of 15%.

In an application with warfarin may affect the prothrombin test indicators: blood clotting time and international normalized ratio.

When combined with ethanol or drugs having gepatoksicheskim action, there is the risk of liver disease drug.

Irregular use of terbinafine or premature discontinuation of treatment may lead to recurrence of the disease. If after 2 weeks of treatment of skin infection is not marked improvement, it is necessary to re-determine the causative agent and its sensitivity to the drug.

Systemic application in onychomycosis is justified only in case of defeat, most nails, availability pronounced subungual hyperkeratosis, ineffectiveness of previous local therapy. In the treatment of onychomycosis clinical response, laboratory confirmed, usually occurs several months after mycological cure and treatment discontinuation rate due to the rate of regrowth of healthy nail. Removal of the nail plate in the treatment of onychomycosis of brushes for 3 weeks and onychomycosis stop for 6 weeks is required.

In the presence of liver disease may be the clearance of terbinafine is reduced. During treatment necessary to control indicators of activity of “liver” transaminases in blood serum.

In rare cases, after 3 months of treatment there is cholestasis and anavar only cycle hepatitis. When liver function disorders symptoms (fatigue, persistent nausea, loss of appetite, excessive abdominal pain, jaundice, dark urine or discolored feces) drug should be discontinued.

Appointment of terbinafine psoriasis patients requires caution, because very rarely terbinafine can cause exacerbation of psoriasis.

In the treatment of terbinafine should comply with the general rules of hygiene to prevent the possibility of re-infection through underwear and shoes. During the treatment (2 weeks) and at the end it is necessary to produce the antifungal treatment of footwear, socks and stockings.

Effects on ability to drive the vehicle and management mechanisms
Terbinafine does not influence the ability to drive and anavar only cycle operate machinery. However, it should be appreciated that the dizziness can occur during treatment.